MedTrace Logo

Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis

NCT07605741 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-05-26

No results posted yet for this study

Summary

Transthyretin cardiac amyloidosis (ATTR-CA) is traditionally diagnosed using planar bone scintigraphy with a Perugini visual score ≥ 2. Fast cardiac CZT-SPECT will be evaluated for its ability to reproduce this classification and provide reproducible quantitative myocardial uptake metrics.

Conditions

  • Cardiac Amyloidosis

Interventions

OTHER

bone scintigraphy

Fast CZT camera bone scintigraphy and bone scintigraphy with conventional camera (standard care)

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-30
Primary Completion
2026-06-30
Completion
2026-07-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07605741 on ClinicalTrials.gov